Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Interferon gamma (IFN-γ) is a cytokine with immunomodulatory and anti-tumor properties. Its use in leukemia, especially chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), has been investigated since the 1980s. Early studies suggested that IFN-γ can enhance the cytotoxic activity of immune cells such as natural killer (NK) cells and macrophages, potentially contributing to anti-leukemic effects. However, most clinical trials and studies have focused on interferon alpha—not gamma—as a treatment for certain leukemias, particularly CML, where interferon alpha was a standard therapy before the advent of tyrosine kinase inhibitors.

For IFN-γ specifically, the evidence supporting its use in leukemia is limited. Some small-scale clinical studies and laboratory experiments have indicated that IFN-γ may have a role in stimulating anti-leukemic immune responses or in enhancing the efficacy of other therapies, such as in the context of minimal residual disease or immunotherapy. However, these effects have not translated into a strong, consistent clinical benefit in large randomized trials. As a result, IFN-γ is not a standard or widely accepted therapy for leukemia, and its use is generally considered experimental or confined to research settings.

In summary, while there is some scientific investigation into the use of IFN-γ for leukemia, the overall quality and quantity of evidence are low (rated 2/5), and it is not a mainstream treatment for this condition.

More about Interferon gamma
More about Leukemia

Other ingredients used for Leukemia

Other health conditions supported by Interferon gamma

Products containing Interferon gamma